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More women are living with and surviving breast cancer, because of improvements in breast cancer care. Trastuzumab
(Herceptin
s.) has significantly improved outcomes for women with HER2-positive tumours. Concerns about the cardiac effects of
trastuzumab (which fundamentally differ from the permanent myocyte loss associated with anthracyclines) led to the development of
cardiac guidelines for adjuvant trials, which are used to monitor patient safety in clinical practice. Clinical experience has shown that
the trial protocols are not truly applicable to the breast cancer population as a whole, and exclude some women from receiving
trastuzumab, even though they might benefit from treatment without long-term adverse cardiac sequelae. Consequently, five
oncologists who recruited patients to trastuzumab trials, some cardiologists with whom they work, and a cardiovascular lead general
practitioner reviewed the current cardiac guidelines in the light of recent safety data and their experience with adjuvant trastuzumab.
The group devised recommendations that promote proactive pharmacological management of cardiac function in trastuzumab-
treated patients, and that apply to all patients who are likely to receive standard cytotoxic chemotherapy. Key recommendations
include: a monitoring schedule that assesses baseline and on-treatment cardiac function and potentially reduces the overall number
of assessments required; intervention strategies with cardiovascular medication to improve cardiac status before, during, and
after treatment; simplified rules for starting, interrupting and discontinuing trastuzumab; and a multidisciplinary approach to breast
cancer care.
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It has been known since the 1960s that some cancer treatments can
affect heart function (Tan et al, 1967). Optimal breast cancer
chemotherapy regimens include multiple agents, some with known
cardiac side effects. Risk factors for the development of
chemotherapy-related congestive heart failure (CHF) include
cumulative anthracycline dose (Von Hoff et al, 1979) and
increasing patient age (Doyle et al, 2005; Pinder et al, 2007). As
the age of the population diagnosed with cancer in the Western
world increases and survival improves, the development of
treatment-related CHF becomes more important.
The addition of trastuzumab to conventional adjuvant (post-
surgical) cytotoxic chemotherapy in individuals with HER2-
positive disease has been one of the most important advances in
the management of early breast cancer. Five trials recruiting more
than 12000 patients with breast cancer have shown a consistent
50% reduction in the risk of recurrence (Piccart-Gebhart et al,
2005; Romond et al, 2005; Joensuu et al, 2006; Slamon et al, 2006;
Smith et al, 2007). However, in the pivotal registration trial of
trastuzumab in metastatic breast cancer, there was an unexpect-
edly high incidence of CHF. This was most evident when
trastuzumab was co-administered with doxorubicin (Seidman
et al, 2002). Concern about cardiac safety influenced the design
of trials evaluating trastuzumab in early breast cancer. In four of
the five studies, trastuzumab followed anthracycline administra-
tion, and prospective cardiac function monitoring was included in
all of the trials. A reduced incidence of heart failure was seen in
these adjuvant (post-surgery) trials, compared with experience in
the metastatic setting (Romond et al, 2005; Tan-Chiu et al, 2005;
Smith et al, 2007; Suter et al, 2007).
The present UK guidance on the use of adjuvant trastuzumab
(NICE, 2006a) is based on the protocol for the European
registration trial (HERceptin Adjuvant; HERA) (Piccart-Gebhart
et al, 2005; Smith et al, 2007). The trial excluded women with a left
ventricular ejection fraction (LVEF) of o55% – a level above the
lower limit of normal (LLN) in many UK institutions. As a result,
current guidance excludes many women with normal cardiac
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sfunction from receiving trastuzumab. Moreover, monitoring
recommendations used serial assessment of LVEF, with interrup-
tion or cessation of trastuzumab in response to changes in LVEF or
symptoms of CHF. There were no recommendations for the
prevention or management of cardiac dysfunction. The limitations
of the strict application of a trial protocol to the whole population
are recognised in the NCRI guidelines for the use of adjuvant
trastuzumab which ‘yare therefore precautionary and may well be
simplified with further clinical experience’ (NCRI, 2005).
AIMS AND METHODOLOGY
Five breast cancer oncologists who contributed to HERA from
regional centres across the United Kingdom, some cardiologists
from the same centres, and a cardiovascular lead general
practitioner, met to consider the available data on the impact of
trastuzumab on cardiac function. They reviewed the present
trastuzumab cardiac guidelines, and drafted new recommenda-
tions based on the latest published data and their combined
experience. These recommendations have been endorsed by the
NCRI.
CHEMOTHERAPY-RELATED CARDIOTOXICITY IN
CLINICAL PRACTICE
During chemotherapy delivery, the clinical focus is appropriately
on acute, often symptomatic, but short-term adverse effects of
drug treatment (Partridge et al, 2001). Acute cardiac effects include
myocardial dysfunction, ischaemia, hypotension, hypertension,
oedema, QT-interval prolongation, bradyarrhythmia, tachyar-
rhythmia, and thromboembolism. These toxicities are associated
with specific drugs, doses, and schedules. In contrast, late-onset
treatment-related cardiac toxicity can significantly affect long-term
quality of life or even increase mortality. Late effects are under-
reported, and can be missed completely if they occur after
specialist follow-up is complete. The importance of the long-term
needs of cancer survivors, particularly the elderly, is increasingly
recognised (Erban and Lau, 2006; Department of Health, 2007).
Anthracycline-related cardiac toxicity is characterised by dose-
related and irreversible loss of cardiac myocytes. There is reduced
contractility in a proportion of the remaining cells (Table 1).
Clinical cardiac failure has been associated with anthracyclines
since 1973 (Lefrak et al, 1973). Characteristic permanent
ultrastructural abnormalities of the myocardium are seen in
endocardial biopsies taken from anthracycline-treated patients
with vacuoles, myofibrillar disarray, and dropout on electron
microscopy. The changes are present from the earliest adminis-
tration of the drug, and have recently been referred to as Type I
chemotherapy-related cardiac dysfunction (CRCD) (Ewer and
Lippman, 2005). The left ventricle is mechanically disadvantaged
and can be in a ‘stressed’ state, but function is optimised by
compensatory mechanisms and there may be no clinically
apparent manifestations for many years.
The incidence and severity of clinically apparent cardiotoxicity
are related to pre-existing medical conditions, previous cardiac
exposure to radiation, and patient age (Tan et al, 1967; Doyle et al,
2005; Ng et al, 2006). There is also a clear relationship between
anthracycline dose, and the incidence of cardiac dysfunction and
clinical heart failure, which has led to restriction of the cumulative
dose of anthracyclines administered (typically o450mgm
 2 for
doxorubicin, o720mgm
 2 for epirubicin) (Von Hoff et al, 1979).
CARDIAC EFFECTS OF TRASTUZUMAB
The cardiac (myocyte) effects of trastuzumab differ fundamentally
from those of anthracyclines; in particular, trastuzumab does not
cause myocyte loss. In patients with trastuzumab-related cardiac
dysfunction, myocytes appear histologically normal; changes may
be seen only by using electron microscopy, in keeping with a
reversible cardiomyopathy (Guarneri et al, 2006), and this has led
to the classification of trastuzumab-related CRCDs as Type II
(Table 1) (Ewer and Lippman, 2005; Guarneri et al, 2006), as
opposed to the irreversible changes associated with anthracyclines
(Type I CRCD).
There is evidence that trastuzumab-related left ventricular
systolic dysfunction (LVSD) is mediated through the binding of
trastuzumab to the extracellular domain of the HER2 protein
present on cardiac myocytes, blocking ErbB2-ErbB4 signalling.
This results in the disabling of an important cell-protective,
growth-promoting pathway within the myocardium. The pathway
is required for cell survival and continuing function, and seems to
be stimulated when the myocardium encounters adverse haemo-
dynamic or other stress, such as that associated with anthracyline
therapy. Withdrawal of trastuzumab allows return of function of
the pathway and reversal of LVEF decline, in contrast to the
permanent myocyte dysfunction and loss caused by anthracy-
clines. This proposed mechanism is consistent with the increase in
cardiac effects when trastuzumab is used concomitantly with
anthracyclines.
The incidence of serious adverse events during trastuzumab
monotherapy is low and the most frequently reported acute
adverse effect of trastuzumab therapy is a hypersensitivity-like
infusion reaction (Adamo et al, 2007; Herceptin PI, 2007). The
antiproliferative side effects commonly associated with cytotoxic
chemotherapy have not been reported. However, when trastuzu-
Table 1 Chemotherapy-related cardiac dysfunction (Ewer and Lippman, 2005)
Type I (myocardial damage) Type II (myocardial dysfunction)
Characteristic agent Doxorubicin Trastuzumab
Clinical course,
response to CRCD therapy
May stabilise, but underlying damage appears to be permanent and
irreversible; recurrence in months or years may be related to
sequential cardiac stress
High likelihood of recovery (to or near baseline cardiac
status) in 2–4 months (reversible)
Dose effects Cumulative, dose-related Not dose-related
Mechanism Free-radical formation, oxidative stress/damage Blocked ErbB2 signalling
Ultrastructure Vacuoles; myofibrillar disarray and dropout; necrosis
(changes resolve over time)
No apparent ultrastructural abnormalities
Non-invasive cardiac testing Decreased ejection fraction by ultrasound or nuclear determination:
global decrease in wall motion
Decreased ejection fraction by ultrasound or nuclear
determination: global decrease in wall motion
Effect of rechallenge High probability of recurrent dysfunction that is progressive, may
result in intractable heart failure and death
Increasing evidence for the relative safety of rechallenge;
additional data needed
Effect of late sequential stress High likelihood of sequential stress-related cardiac dysfunction Low likelihood of sequential stress-related cardiac dysfunction
Abbreviation: CRCD¼chemotherapy-related cardiac dysfunction. Reproduced with permission from the American Society of Clinical Oncology, from Ewer and Lippman, 2005.
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CHF was reported in an unexpectedly high number of patients,
prompting a detailed retrospective cardiac evaluation (Slamon
et al, 2001). Anthracycline-naive patients received doxorubicin,
and anthracycline-pretreated patients received paclitaxel, to avoid
an excessive cumulative anthracycline dose. Paclitaxel monother-
apy was associated with a 1% incidence of CHF; concurrent use of
trastuzumab increased this to 13%. Patients receiving concurrent
anthracycline and trastuzumab had a 27% incidence of sympto-
matic heart failure (16% NYHA Grade III/IV). Trastuzumab-
associated LVSD was not dose-related, and appeared to improve
with standard medical management including angiotensin-
converting enzyme (ACE) inhibitors.
In adjuvant trials, there were stringent cardiac eligibility criteria,
and trastuzumab was interrupted or discontinued in response to
the development of CHF or following protocol-defined changes in
LVEF. In a large North American study (NSABP B-31) (Rastogi
et al, 2007), patients with HER2-positive, node-positive early
breast cancer, and an LVEF 450% received 4 cycles of
anthracycline-containing chemotherapy followed by 4 cycles of
paclitaxel. Patients were randomised to receive trastuzumab for a
total of 1 year, starting concurrently with paclitaxel. In the control
arm (no trastuzumab), 10 of 872 (1.3%) patients with a normal
post-anthracycline LVEF had confirmed cardiac events (9 CHF, 1
death), compared with 35 of 932 (3.9%) patients in the
trastuzumab-treated arm (35 CHF, no deaths). Trastuzumab was
discontinued because of cardiac dysfunction in 15.6% of patients.
Age 450 years, prescription of antihypertensive medication, and
post-anthracycline LVEF values of 50–54% (0.50–0.54) were all
associated with an increased risk of CHF.
The European HERA trial evaluated the effects of using
trastuzumab after completion of all chemotherapy; 94% of patients
received anthracyclines. A post-chemotherapy LVEF of 55% was
required in HERA, compared with 50% in the US study, and there
was an in-built delay of several months between the completion of
(cytotoxic) chemotherapy and initiation of trastuzumab (for either
1 or 2 years). No cardiac deaths occurred, the rate of severe heart
failure was o1% (Smith et al, 2007; Suter et al, 2007), and only
4.3% of patients discontinued trastuzumab because of cardiac
dysfunction (Suter et al, 2007). The reduction in cardiac event rate
has been attributed to the higher baseline LVEF requirement and
the protocol-driven delay between the end of cytotoxic therapy and
start of trastuzumab (Smith et al, 2007). Experience from one US
cancer centre showed a median time to decline in LVEF during
trastuzumab therapy of 4.5 months (Ewer et al, 2005). After
cessation of trastuzumab (37 of 38 patients), and commencement
of standard treatment for LVSD (31 patients), the mean time to
recovery of LVEF was 1.5 months.
REVISED TREATMENT AND MONITORING
ALGORITHM FOR TRASTUZUMAB
The current algorithm for monitoring LVEF and interrupting
trastuzumab treatment was derived from the HERA clinical trial
protocol (Figure 2). The high incidence of cardiac dysfunction seen
in the preceding metastatic breast cancer trials led to stringent
inclusion criteria, and many women with normal left ventricular
function were excluded from the trial. There was no attempt to
ameliorate cardiac risk factors or actively manage asymptomatic
LVEF decline during the study, and the only permissible response
was interruption or discontinuation of drug. There is greater
understanding of the pathophysiology of trastuzumab-related
LVSD, and in particular its potential reversibility. The clinical
trial population does not map onto the whole population of women
with HER2-positive breast cancer, some of whom, on the basis of
arbitrarily set cardiac criteria, are excluded from receiving
trastuzumab, even though they might benefit from treatment
without long-term adverse cardiac sequelae. The algorithm has
been re-evaluated to allow proactive intervention that facilitates
the initiation and continuation of trastuzumab therapy, where it
may previously have been omitted or discontinued.
KEY RECOMMENDATIONS
Baseline cardiac assessments before cytotoxic
chemotherapy
Patients receiving chemotherapy may be considered to be at
increased risk of developing cardiac dysfunction – Stage A heart
failure in ACC/AHA guidelines (Bonow et al, 2005). The following
assessments are recommended before initiating chemotherapy, for
all patients with HER2-positive breast cancer. Although these
recommendations relate only to HER2-positive tumours, similar
pre-treatment assessments would be desirable in any patient for
whom cytotoxic chemotherapy is being considered.
  Medical history
* To determine previous cardiac events and risk factors.
  Physical examination
* Blood pressure (hypertension is a potent and modifiable risk
factor for the development of cardiac dysfunction, and
should be assessed before each cycle of treatment – a blood
pressure of 4140/85mmHg should be treated with an ACE
inhibitor).
* Auscultation of the heart to identify murmurs (significant
valvular heart disease is a risk factor for cardiac dysfunction).
* Signs of heart failure (raised venous pressure, crepitations
over the lung fields or pedal oedema).
  12-lead electrocardiogram (ECG) – looking for possible markers
of structural heart disease including left ventricular damage/
dysfunction
* For arrhythmias (atrial fibrillation, atrial flutter, heart block).
* For evidence of previous myocardial infarction (Q-waves, left
bundle branch block).
* For evidence of left ventricular hypertrophy.
  Left ventricular ejection fraction measurement using Echo or
radionucleotide multiple-gated acquisition (MUGA) scan.
* This baseline test is not recommended in present NCRI
guidelines. The associated resource use is offset by a
reduction in the requirement for testing during trastuzumab
administration.
In routine clinical practice, LVEF can be measured with Echo or
radionucleotide MUGA scan. Where the ECG is significantly
abnormal at baseline, Echo is recommended whenever satisfactory
images can be obtained, because it provides additional information
on heart valve function.
Serial LVEF assessments are required to guide treatment, and a
high degree of reproducibility is essential; MUGA has some
advantages in this respect, but requires the use of significant
ionising radiation (Healthcare Commission, 2000). The same
monitoring modality should be used throughout the course of
treatment and, where possible, this should also include the same
operator, machine, and calculation algorithm. Each institution
should establish a normal range for the methods used. Left
ventricular ejection fraction is a dynamic physiological function
varying from day to day depending on heart rate and loading
conditions, but every effort must be made to provide an accurate
and precise assessment of LVEF to guide clinical decisions about
trastuzumab therapy, in the same way as this information is
essential for implantable cardioverter defibrillator (NICE, 2006b)
and cardiac resynchronisation therapies (NICE, 2006c). Clinicians
interpreting LVEF values should consider confounding factors if
they receive unexpected results.
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sInterventions at baseline
Referral to a cardiologist This is recommended for patients who
have evidence of LVSD, cardiac dysrhythmias, or structural heart
disease, including evidence of previous infarction or significant
modifiable cardiovascular risk factors, such as poorly controlled
hypertension.
Modification of planned chemotherapy regimen Assessment of
baseline LVEF before chemotherapy in all patients informs the
choice of cytotoxic regimen. Patients with low or borderline LVEF
may benefit from a non-anthracycline-containing regimen. The
combination of docetaxel and cyclophosphamide has been
compared with doxorubicin and cyclophosphamide, and has
shown at least equivalent efficacy (Jones et al, 2006). Prophylactic
ACE inhibitor therapy may also be considered for such patients.
The use of ACE inhibitors to control hypertension Hypertension is
a potent modifiable risk factor for the development of heart failure
during breast cancer treatment, with a statistically significant
hazard ratio of 1.45 (95% CI, 1.39–1.52) (Pinder et al, 2007). Blood
pressure should be measured in all breast cancer patients at
routine oncology clinic visits, and where readings are above the
second Joint British Societies’ guidelines (British Cardiac Society
et al, 2005), target of o140/85mmHg, they should be treated with
an ACE inhibitor licensed for the treatment of heart failure
(Table 2). Angiotensin-converting enzyme inhibitors are recom-
mended as first-line antihypertensive agents. Trial data support
their efficacy in reducing blood pressure, and for the prevention
and treatment of left ventricular dysfunction and heart failure
(SOLVD Investigators, 1992; AIRE Investigators, 1993; Moye ´ et al,
1994; Arnold et al, 2003). There is also direct trial evidence for the
efficacy of ACE inhibitors in preventing the decrease in LVEF
observed in patients after high-dose chemotherapy (Cardinale
et al, 2006).
It is recommended that dose titration and renal function
monitoring be performed in primary care in accordance with
current cardiac guidance (NICE, 2003). Patients with breast cancer
whose hypertension cannot be controlled with standard pharma-
cological treatment should be referred to a specialist.
Lifestyle recommendations Patients should be advised by their
GP and oncologist about lifestyle changes that reduce their
cardiovascular risk:
  Smoking cessation.
  Improving diet.
* Moderate alcohol consumption (up to 14 units a week for
women – heavy alcohol consumption can both increase blood
pressure and reduce cardiac function).
* Reducing dietary salt.
* Reducing fat.
* Increasing fruit and vegetable consumption (five a day).
  Increasing physical activity.
  Weight loss where appropriate.
Management of cardiac function during trastuzumab
Use of the present algorithm for monitoring cardiac function in
trastuzumab-treated patients (Figure 1) has resulted in a low
incidence of clinical heart failure in routine practice. However, the
algorithm has a number of limitations. Specifically, it:
  Is susceptible to misinterpretation.
  Requires the determination of LVEF with a precision and
reproducibility, that cannot often be achieved in routine clinical
practice.
  Does not take account of the normal ranges for LVEF of
different imaging modalities, in different institutions.
  Requires a high frequency of monitoring compared with the risk
of clinical heart failure.
  Does not specify a pre-chemotherapy LVEF assessment as a
baseline for the evaluation of cytotoxic drug-related cardiac
damage and dysfunction.
  Does not provide guidance for the optimisation of cardiac
health before trastuzumab therapy.
  Does not make recommendations on the treatment of patients
with LVSD other than the interruption of trastuzumab therapy.
  Does not facilitate successful rechallenge with trastuzumab.
ASSESSMENT OF LVEF BEFORE TRASTUZUMAB
TREATMENT
Left ventricular ejection fraction should be further assessed in all
patients after completion of chemotherapy and before initiating
trastuzumab therapy (Figure 2). Some patients (7% in NASBP-B31)
will experience a decrease in LVEF that precludes trastuzumab
treatment (Romond et al, 2005). These patients are not eligible to
commence trastuzumab and should be started on an ACE inhibitor
and referred to a cardiologist. Repeat assessment of cardiac
function should take place after 3 months (but before the time
window for starting trastuzumab specified by NICE expires).
A significant decrease in LVEF (e.g., 0.10 points) during the
course of anthracycline chemotherapy is most likely to indicate a
left ventricle that has been left in a damaged, haemodynamically
compromised state, and is thus at increased susceptibility to
trastuzumab. Prophylactic ACE inhibitor therapy may therefore be
considered for such patients.
INITIATION OF TRASTUZUMAB THERAPY
Trastuzumab may be initiated in patients with LVEF above the
LLN for the institution (Figure 2A and D).
MONITORING FREQUENCY
Routine LVEF monitoring is recommended at 4 and 8 months. A
further assessment at the end of treatment is recommended for
patients requiring cardiovascular intervention during treatment.
The minimum number of LVEF assessments when following this
recommendation is four, compared with five using the NCRI
guidelines. Additional testing is required in patients who have
Table 2 Currently available ACE inhibitors licensed for heart failure, and
their recommended dosing schedules (BNF, 2007)
ACE inhibitor Starting dose Dose titration
Captopril 6.25–12.5mg twice Maintenance: 25–50mg twice daily
daily Maximum: 150mg daily in divided
doses
Cilazapril 0.5mg once daily Maintenance: 2.5–5mg once daily
Maximum: 5mg once daily
Enalapril maleate 2.5mg once daily Maintenance: 20mg once daily
Maximum: 10–20mg twice daily
Fosinopril sodium 10mg once daily Maintenance: 10–40mg once daily
Maximum: 40mg once daily
Lisinopril 2.5mg once daily Maintenance: 20mg once daily
Maximum: 35mg once daily
Perindopril 2mg once daily Maintenance: 4mg once daily
erbumine Maximum: 4mg once daily
Quinapril 2.5mg once daily Maintenance: 10–20mg once daily
Maximum: 40mg once daily
Ramipril 1.25mg once daily Maintenance: 2.5–5mg once daily
Maximum: 10mg once daily
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in the present guidance. This slightly reduced frequency of
monitoring reflects the more proactive approach to preventing
cardiac events, and increased understanding of the time course
and reversibility of trastuzumab-induced LVSD.
SYMPTOMATIC HEART FAILURE
Patients developing signs and symptoms of heart failure should
have their trastuzumab treatment interrupted, have ACE inhibitor
therapy initiated by the oncologist, and be referred to a
cardiologist. Investigation and treatment is recommended in
accordance with present guidelines (NICE, 2003; Bonow et al,
2005; Swedberg et al, 2005).
ASYMPTOMATIC DECREASE IN LVEF
For the purposes of these recommendations, an LVEF of 0.40 or
less has been taken to represent biologically important LVSD. This
is in keeping with the many studies showing that at this level of
LVEF, intervention with pharmacotherapy influences an otherwise
adverse outcome.
LVEF  44
Hold trastuzumab
Repeat LVEF in 3 weeks
 10 EF points from baseline
Hold trastuzumab
Repeat LVEF in 3 weeks
< 10 EF points 
from baseline
Continue
trastuzumab
Resume trastuzumab Resume trastuzumab Stop trastuzumab Stop trastuzumab
Continue
trastuzumab
LVEF   44 
or
LVEF 45–49 and
 10 points from baseline
LVEF 45–49
LVEF 45–49
< 10 points from baseline
or LVEF > 49
LVEF 45–49 and
< 10 points from baseline
or LVEF > 49
LVEF  44
or
LVEF 45–49 and
 10 points from baseline
LVEF < 50 LVEF  50
Figure 1 Current recommendations for cardiac monitoring in trastuzumab-treated patients (reproduced from Suter et al, 2007; online Appendix only).
Reproduced with permission of the American Society of Clinical Oncology, from Suter et al, 2007.
Patient assessment
< 0.10 None
None
Any
 0.10
–
 LLN
> 0.40
 0.40
Signs or 
symptoms
LVEF = left ventricular ejection fraction
LLN = lower limit of normal
Post-chemotherapy
Trastuzumab
Start trastuzumab NO NO
REFER
REFER
YES
YES
Defer until ‘green’ *
Not recommended
Start ACEi Cardiology
*For patients with LVEF < LLN,  cardiac function should
 be optimised and reassessed 3 months later
During trastuzumab
Trastuzumab
Continue NO NO NONE
6–8 weeks after 
first amber
End of treatment
Within 6 weeks
then as clinically
indicated
REFER
if on ACEi YES
REFER YES
Continue
STOP*
Cardiology Start 
ACEi
Additional 
monitoring
*May restart if ‘green’ after consideration of risk vs benefit
Pre-chemotherapy
Treatment
Standard CT NO NO
REFER
REFER
YES
YES
Consider CT*
Consider CT*
Start ACEi Cardiology
*Consider non-anthracycline chemotherapy (CT)
A
CD
B
LVEF value
> LLN
LVEF decrease 
during trastuzumab
Figure 2 Traffic light system to prevent, monitor, and manage cardiac events in patients undergoing cytotoxic chemotherapy. (A) Patient assessment
during trastuzumab therapy; (B–D) indications for ACEi therapy and referral to a cardiologist before (B) and after (C) chemotherapy, and (D) during
trastuzumab therapy, when additional cardiac assessments may also be required. ACEi¼angiotensin-converting enzyme inhibitor.
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interrupted, as significant LVSD has occurred. An ACE inhibitor
should be started by the oncologist, and the patient should be
referred to a cardiologist. Investigation and treatment is recom-
mended in accordance with national and international guidelines
on the management of CHF in adult (NICE, 2003; Bonow et al,
2005; Swedberg et al, 2005). The LVEF measurement should be
repeated after 6–8 weeks. Trastuzumab may be re-initiated if the
LVEF is restored to a level above the LLN.
If the LVEF decreases to below the LLN but 40.40, trastuzumab
may be continued, but an ACE inhibitor should be initiated. If this
decrease occurs despite pre-existing ACE inhibitor therapy, the
patient should be referred to a cardiologist. Monitoring should be
repeated after 6–8 weeks. This may require a cultural shift among
senior oncologists, but the members of the group have embraced
this change in practice, which is working well in their centres. In
the past decade, ACE inhibitor therapy has become the standard of
care in the treatment of hypertension, primary and secondary
prevention of cardiovascular disease, heart failure, and renal
impairment. There are robust trial data to support these
treatments, which are now often initiated, and almost universally
monitored and titrated, in primary care. Angiotensin-converting
enzyme inhibitors are some of the most widely used drugs in
modern cardiology. They are very effective in a wide range of
cardiovascular conditions, including asymptomatic LVSD (Moye ´
et al, 1994), heart failure due to LVSD (CONSENSUS Trial Study
Group, 1987; SOLVD Investigators, 1991), LVSD following a
myocardial infarction (Pfeffer et al, 1992; AIRE Investigators, 1993;
Torp-Pedersen and Køber, 1999), hypertension (Dahlo ¨f et al,
2005), and stable coronary artery disease (Yusuf et al, 2000; Fox
et al, 2003). Their use is now included in all the major national and
international guidelines for the treatment of these conditions, both
in primary and secondary care.
If the LVEF decreases by 0.10 points or more and remains above
the LLN, trastuzumab may be continued, but an ACE inhibitor
should be initiated. Monitoring should be repeated after 6–8
weeks. A decrease of 0.10 or more may suggest an increased risk of
heart failure, and intervention with an ACE inhibitor is
recommended to reduce this risk.
TRAFFIC LIGHT SYSTEM
Navigation through these recommendations may be facilitated by
the adoption of a traffic light system (Figure 2).
  A green light indicates LVEF above the LLN, no signs or
symptoms of CHF and any trastuzumab-related LVEF decrease
being o0.10.
  An amber light indicates LVEF between the LLN and 0.40, with
no signs or symptoms of CHF, or a trastuzumab-related LVEF
reduction of 0.1 or more.
  A red light indicates LVEF p0.40 or symptoms and signs of
cardiac failure.
Before chemotherapy (Figure 2B), green indicates go. Red or
amber indicates careful consideration of decision to start
chemotherapy, with consideration of non-anthracycline-contain-
ing regimens. Both amber and red are indications for the initiation
of ACE inhibitors and referral to cardiology for the optimisation of
cardiac function.
Post-chemotherapy (Figure 2C), green indicates go. Amber
indicates defer until green. Red indicates that it is unlikely to be
safe to start trastuzumab. Both amber and red are indications for
the initiation of ACE inhibitors and referral to cardiology for the
optimisation of cardiac function. It is recommended that LVEF is
reassessed after 3 months, and that trastuzumab is not commenced
unless LVEF is within normal limits at that point.
During trastuzumab (Figure 2D), green is an indication to
continue treatment. Amber is also an indication to continue
treatment, but patients should also be taking an ACE inhibitor.
Patients who drop into the amber range while on an ACE inhibitor
should be referred for a cardiology opinion. Red is an indication to
interrupt trastuzumab, start on an ACE inhibitor if applicable, and
refer for a cardiology opinion.
Patients whose trastuzumab is interrupted (i.e., red light) should
not restart until LVEF is within the normal range (i.e., green light).
MONITORING PROCEDURES IN EARLY AND
METASTATIC BREAST CANCER
These recommendations were primarily developed for use in
patients with early breast cancer who are expected to complete a
full 12-month course of trastuzumab therapy. In patients with
metastatic breast cancer, trastuzumab is continued until disease
progression, but the recommendations are still suitable for
monitoring cardiac effects during the first few months of therapy.
During trastuzumab therapy, patients with metastatic breast cancer
should be monitored for 8 months according to our recommenda-
tions. Assuming no complications have occurred, cardiac monito-
ring should be performed at the discretion of the treating physician,
after discussion with the patient, and in accordance with local
guidelines. Patients with metastatic disease have a very different
oncology risk profile to those receiving adjuvant treatment; the
monitoring strategy and thresholds for treatment discontinuation
should thus be individualised in consultation with the oncologist
and cardiologist when appropriate.
PROPOSAL FOR PROSPECTIVE AUDIT
The primary aim of reviewing the cardiac monitoring guidance for
trastuzumab was to re-evaluate the present guidelines, based on
the latest safety data and extensive clinical experience using
adjuvant trastuzumab. These recommendations consider the best
available present evidence and the application of data from large
cardiovascular trials. Data obtained from retrospective review of
trastuzumab-treated patients will be compared with prospective
audit data generated from the use of these new recommendations;
a separate prospective audit of the recommendations is also
planned. The oncologists who participated in the development of
the recommendations have adopted the practices outlined in the
treatment algorithm, and audit is already underway in their
centres. Audit findings will be published as soon as sufficient
follow-up data are available.
CONCLUSIONS
The present guidelines for cardiac monitoring in patients receiving
trastuzumab reflect clinical trial design, rather than the whole
population of patients with HER2-positive breast cancer. Experi-
ence gained through implementation of national guidance led
oncologists, cardiologists, and a cardiovascular lead GP to review
the evidence base for managing cardiac safety in trastuzumab-
treated patients, and to draft revised recommendations. The
proposed changes to the present NCRI guidelines are designed to
promote a proactive approach to the management of cardiac
function.
The key recommendations from this review are as follows:
  Cardiac assessment, including LVEF measurement, should be
performed before any chemotherapy.
  Heart function measurement should be referenced to the local
normal range for the modality used.
  Management of cardiac risk factors including hypertension
before the first cycle of chemotherapy.
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before starting trastuzumab.
  Repeat measurements should be performed after 4 and 8
months of trastuzumab treatment.
  Simplified trastuzumab treatment interruption recommendations.
  Clear advice on initiating an ACE inhibitor and when to consult
a cardiologist.
  Recommendations for restarting trastuzumab.
  Guidance that applies to both early and metastatic breast
cancer.
  Protocols that promote a multidisciplinary approach to patient
care.
These recommendations have the potential to improve the care
of patients with HER2-positive breast cancer by increasing safe
access to evidence-based treatment with proven disease-free
survival and mortality benefits. Spacing of cardiac assessments
and omission of the end of treatment of LVEF assessment in
patients without evidence of cardiac dysfunction can reduce the
overall number of LVEF assessments performed. We strongly
advocate collaboration in audit across the United Kingdom to
evaluate their effects.
As a first-in-class drug, trastuzumab raises the challenge of
managing cardiac function in patients receiving anti-HER2
therapies. Other new targeted agents are also associated with
cardiac concerns, and these recommendations may be suitable,
with appropriate prospective audit, to monitor cardiac function
with these other drugs.
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